REMEMBER!!! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

STAY TUNED!! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

WHAT’S NEW? To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

REMEMBER! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

DID YOU DO IT? To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

DON’T FORGET! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

DON’T FORGET! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

DON’T FORGET! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

📖 Read the full publication & see the visual abstract: Frontiers Publishing Partnerships | Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus Register here: go.esot.org/ti_jc17march (6/6)

🚨 Why is this important? Highly sensitized patients face longer wait times, fewer organ offers, & higher rejection risk. Imlifidase, a rapid IgG-cleaving enzyme, may change this—but clinical guidance is needed! This expert consensus aims to bridge that gap. (2/6)